Abstract
The process of protein prenylation involves the covalent linkage of either farnesyl (15-carbon) or geranylgeranyl (20-carbon) isoprenoid lipds to conserved cysteine residues in the carboxyl-terminus of proteins. Protein geranylgeranyltransferase I (GGTase-I) is the enzyme that catalyzes the addition of the geranylgeranyl moiety from geranylgeranyl pyrophosphate to the target protein, which contains a Cterminal consensus sequence termed a CaaX motif. Geranylgeranylation is important to the function of a number of proteins, including the majority of Rho GTPases, G protein gamma subunits, and several other regulatory proteins. Studies over the past two decades have revealed that many of these proteins contribute to tumor development and metastasis. Blocking Rho GTPase activity through inhibition of GGTase-I in particular has been advanced as a potential strategy for disease therapy. This review will provide an overview of the CaaX prenyltransferases, the rationale for targeting GGTase-I in cancer in particular, and the current status of GGTase-I inhibitor (GGTI) development.
Keywords: Prenylation, isoprenylation, isoprenoid, CaaX protein, GGTI, FTI, geranylgeranyl, farnesyl.
Current Cancer Drug Targets
Title:Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Volume: 16 Issue: 7
Author(s): Nisar Ullah, Muhammad Mansha and Patrick J. Casey
Affiliation:
Keywords: Prenylation, isoprenylation, isoprenoid, CaaX protein, GGTI, FTI, geranylgeranyl, farnesyl.
Abstract: The process of protein prenylation involves the covalent linkage of either farnesyl (15-carbon) or geranylgeranyl (20-carbon) isoprenoid lipds to conserved cysteine residues in the carboxyl-terminus of proteins. Protein geranylgeranyltransferase I (GGTase-I) is the enzyme that catalyzes the addition of the geranylgeranyl moiety from geranylgeranyl pyrophosphate to the target protein, which contains a Cterminal consensus sequence termed a CaaX motif. Geranylgeranylation is important to the function of a number of proteins, including the majority of Rho GTPases, G protein gamma subunits, and several other regulatory proteins. Studies over the past two decades have revealed that many of these proteins contribute to tumor development and metastasis. Blocking Rho GTPase activity through inhibition of GGTase-I in particular has been advanced as a potential strategy for disease therapy. This review will provide an overview of the CaaX prenyltransferases, the rationale for targeting GGTase-I in cancer in particular, and the current status of GGTase-I inhibitor (GGTI) development.
Export Options
About this article
Cite this article as:
Ullah Nisar, Mansha Muhammad and Casey J. Patrick, Protein Geranylgeranyltransferase Type 1 as a Target in Cancer, Current Cancer Drug Targets 2016; 16 (7) . https://dx.doi.org/10.2174/1568009616666151203224603
DOI https://dx.doi.org/10.2174/1568009616666151203224603 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polo-Like Kinases (Plks) are Prognostic Markers for Gynecologic Malignancies
Current Women`s Health Reviews Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Gene Regulation in Cancer Gene Therapy Strategies
Current Medicinal Chemistry A Fatal Case of Acute Interstitial Pneumonia (AIP) in a Woman Affected by Glioblastoma
Current Drug Safety Functional Genomics Approaches in Cancer Research
Current Genomics Anticancer and Antibacterial Activity of Hyperforin and Its Derivatives
Anti-Cancer Agents in Medicinal Chemistry Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry Editorial (Thematic Issue: Self-Assembled Organic Nanostructures in Medicinal Chemistry: Advances and Applications)
Current Topics in Medicinal Chemistry Actions of the Anti-Angiogenic Compound Angiostatin in an Animal Model of Alzheimer’s Disease
Current Alzheimer Research Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellular Efflux of cAMP and cGMP - A Question about Selectivity
Mini-Reviews in Medicinal Chemistry The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry Current Approaches for Drug Delivery to Central Nervous System
Current Drug Delivery